Promoting the Development of Health Technologies to Meet Global Needs to Manage Antibiotic Resistance
For many years, the research and development (R&D) of new antibacterial drugs kept pace with that of bacterial resistance. During the 1940s through the 1960s, numerous antibiotics were developed, but in the late 60's it all came to a sudden halt and no new antibiotics classes were introduced until the year 2000. Since then the pipeline is running on empty.
ReAct has worked assiduously to push this critical issue on to the political agenda, and to maintain the political momentum remains one of our main tasks.
Our work also includes shepherding the development of new funding mechanisms as well as re-engineering the R&D pipeline in order to create an enabling environment for novel, reliable, and affordable health products, from drugs to diagnostics and vaccines.
TREATMENT FOR TOMORROW (T4T)
T4T: Finding Breakthrough Innovations for Tackling Antibiotic Resistance. A project initiated in 2011 run by ReAct at Duke University exploring the realignment of incentives to balance affordable access with rational use of antibiotics. A stakeholder meeting was hosted by Duke in December 2012.
COLLABORATION FOR INNOVATION
High-level meeting organized by ReAct, “Collaboration for Innovation – The Urgent Need for New Antibiotics”, in Brussels on May 23rd.
THE BEGINNING OF A NEW ERA IN ANTIBIOTIC DEVELOPMENT
ReAct seminar in Brussels on March 29, 2011, co-hosted with the European Parliament-
THE GLOBAL NEED FOR EFFECTIVE ANTIBIOTICS
Invitational conference organized by ReAct and Uppsala University, September 2010.
Conclusions from the conferece published in Drug Resistance Updates 14/2011